dc.contributor.author | Wenzler, Tanja | |
dc.contributor.author | Yang, Sihyung | |
dc.contributor.author | Patrick, Donald A. | |
dc.contributor.author | Braissant, Olivier | |
dc.contributor.author | Ismail, Mohamed A. | |
dc.contributor.author | Tidwell, Richard R. | |
dc.contributor.author | Boykin, David W. | |
dc.contributor.author | Wang, Zhuo | |
dc.contributor.author | Brun, Reto | |
dc.date.accessioned | 2015-12-31T18:13:09Z | |
dc.date.available | 2015-12-31T18:13:09Z | |
dc.date.issued | 2014-05-27 | |
dc.identifier.citation | Wenzler, T., S. Yang, D. A. Patrick, O. Braissant, M. A. Ismail, R. R. Tidwell, D. W. Boykin, M. Z. Wang, and R. Brun. "In Vitro and In Vivo Evaluation of 28DAP010, a Novel Diamidine for Treatment of Second-Stage African Sleeping Sickness." Antimicrobial Agents and Chemotherapy 58.8 (2014): 4452-463. http://dx.doi.org/10.1128/AAC.02309-13 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/19370 | |
dc.description | This is the published version. | en_US |
dc.description.abstract | African sleeping sickness is a neglected tropical disease transmitted by tsetse flies. New and better drugs are still needed especially for its second stage, which is fatal if untreated. 28DAP010, a dipyridylbenzene analogue of DB829, is the second simple diamidine found to cure mice with central nervous system infections by a parenteral route of administration. 28DAP010 showed efficacy similar to that of DB829 in dose-response studies in mouse models of first- and second-stage African sleeping sickness. The in vitro time to kill, determined by microcalorimetry, and the parasite clearance time in mice were shorter for 28DAP010 than for DB829. No cross-resistance was observed between 28DAP010 and pentamidine on the tested Trypanosoma brucei gambiense isolates from melarsoprol-refractory patients. 28DAP010 is the second promising preclinical candidate among the diamidines for the treatment of second-stage African sleeping sickness. | en_US |
dc.publisher | American Society for Microbiology | en_US |
dc.relation.isversionof | 10.1128/AAC.02309-13 | en_US |
dc.title | In Vitro and In Vivo Evaluation of 28DAP010, a Novel Diamidine for Treatment of Second-Stage African Sleeping Sickness | en_US |
dc.type | Article | |
kusw.kuauthor | Wang, Zhuo | |
kusw.kudepartment | Pharmaceutical Chemistry | en_US |
kusw.oanotes | Per SHERPA/RoMEO, 12/31/15: Author's Pre-print: green tick author can archive pre-print (ie pre-refereeing)
Author's Post-print: green tick author can archive post-print (ie final draft post-refereeing)
Publisher's Version/PDF: green tick author can archive publisher's version/PDF
General Conditions: Author's pre-print on recognised non profit pre-print archives
Author's post-print on funder's repositories, institutional repository or subject-based repositories
Non-commercial
Publisher's version/PDF may be used
Publisher's version/PDF may be used on author's personal website or employers website
Recommended that author's post-prints submitted to PubMed or institutional repositories are made available 6 months after publication
Author's pre-print must be updated with citation and DOI upon publication | en_US |
dc.identifier.orcid | https://orcid.org/0000-0003-1751-4975 | |
kusw.oaversion | Scholarly/refereed, publisher version | |
kusw.oapolicy | This item meets KU Open Access policy criteria. | |
dc.rights.accessrights | openAccess | |